Closing the Gap: Innovation vs Access in Blood Cancer Care

Multiple myeloma was once described as a death sentence. Today, thanks to proteasome inhibitors, immunomodulatory drugs (IMiDs), anti-CD38 antibodies, and chimeric antigen receptor (CAR) T-cell therapy, patients are living years—sometimes decades—longer than previous survival estimates. Similar transformations are underway across acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and beyond, as cell-based therapies move from experimental to standard of care.